LGNDZ OTC
Ligand Pharmaceuticals, Inc.
1W: +19.8%
1M: +42.2%
3M: -77.7%
YTD: -66.5%
$0.00
+0.00 (+33.88%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.0M
52W Range0.0017-0.002276
Volume4,512
Avg Volume57,558
Beta0.98
Dividend—
Analyst Ratings
Company Info
CEOTodd C. Davis
Employees47
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2022-11-01
Websiteligand.com
555 Heritage Drive
Jupiter, FL 33458
US
Jupiter, FL 33458
US
+1 858 550 7500
About Ligand Pharmaceuticals, Inc.
Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its comprehensive product line features treatments such as evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was established in 1987 by Ronald M. Evans and is headquartered in Jupiter, Florida.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Reardon Andrew | J-Other | 179 | $60.71 | 2023-12-29 |
| Espinoza Octavio | F-InKind | 1,269 | $59.61 | 2023-12-05 |
| Korenberg Matthew E | F-InKind | 1,984 | $59.61 | 2023-12-05 |
| Espinoza Octavio | F-InKind | 346 | $59.92 | 2023-10-01 |
| Zimmermann Martine | A-Award | 2,285 | — | 2023-09-22 |